FAMCYCLOVIR FOR WILD TYPE (HBEAG+) HEPATITIS B

泛昔洛韦治疗野生型 (HBEAG) 乙型肝炎

• 批准号: 6307333
• 负责人: PAUL J POCKROS
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307333
• 关键词: antiviral agents; clinical research; hepatitis B; hepatitis B virus group; human subject; human therapy evaluation; microorganism disease chemotherapy

The aim of this study is to evaluate the safety and efficacy of Famcyclovir at doses of 500 mg three times a day and 1.5 grams once a day for 52 weeks for the treatment of chronic hepatitis B. Efficacy is determined by HBV DNA and HBeAg.

本研究的目的是评估Famcyclovir治疗慢性乙型肝炎的安全性和有效性，剂量为500 mg，每天3次，1.5 g，每天1次，持续52周。疗效由HBV DNA和HBeAg决定。